Dhaka, Oct. 26 -- The Beximco Pharmaceuticals will make available 'Triko', its brand medicine for generic version of Trikafta used to treat Cystic fibrosis (CF), at an affordable cost from spring 2026. CF is a life-threatening genetic disorder with very low life expectancy, says a press release.

Triko will cost US$ 12,750 per year for an adult patient while, for a child, it will cost US$6,375 per year.

The cost of Trikafta, a triple combination therapy for CF containing elexacaftor, tezacaftor and ivacaftor, produced by the US-based Vertex Pharmaceuticals is US $370,000 for a child per year. Unfortunately, very few patients can have access to this blockbuster drug due to exorbitant cost.

On this grim backdrop, a group of mothers whose ...